Kilter Group’s Ascendis Pharma A/S ASND Stock Holding History

Kilter Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$199	–	1408
2025 Q3	$199	Buy	+1	New	+$187	﹤0.01%	1175

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Kilter Group's ASND Position: Q4 2025 in Review

Kilter Group sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 1 share — an estimated $199 sold.

Kilter Group first reported a position in ASND in Q3 2025 and held it in 1 quarter. The position peaked at $199 in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Kilter Group reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Kilter Group sold 1 Ascendis Pharma A/S share in Q4 2025, an estimated $199.
Kilter Group first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 1 quarter.
Kilter Group's Ascendis Pharma A/S position peaked at $199 in Q3 2025.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Kilter Group's 13F filing for Q4 2025, filed 13 Feb 2026.